Spotlight On Alzheimer's Disease
More than 6 million Americans are currently living with Alzheimer's, and that number is only expected to increase. In fact, estimates now show that this number could rise to nearly 13 million by 2050.
To help optimize the care of patients living with this debilitating condition, Spotlight on Alzheimer’s Disease features leading neurologists and other allied healthcare professionals sharing their insights on the latest diagnostic and treatment advances.
1-15 of 28
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
NeuroFrontiersAdvances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
Marc Haut, PhD
Transforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
NeuroFrontiersTransforming Alzheimer’s Care: Anti-Amyloid Therapies and Emerging Genetic Approaches
Marc Haut, PhD
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
NeuroFrontiersEpigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
David Gate, PhD
Restoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
NeuroFrontiersRestoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
Early Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
NeuroFrontiersEarly Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
NeuroFrontiersMetabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
- advertisement
Beyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
NeuroFrontiersBeyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
Thomas Karikari, PhD
Preventing Alzheimer’s Disease Through Lifestyle Interventions
NeuroFrontiersPreventing Alzheimer’s Disease Through Lifestyle Interventions
Michele Longo, MD
Amyloid-Targeted Therapies: A New Era in Alzheimer’s Disease Treatment
NeuroFrontiersAmyloid-Targeted Therapies: A New Era in Alzheimer’s Disease Treatment
Michele Longo, MD
Researching the Overlap: Hepatic Encephalopathy and Dementia in Focus
NeuroFrontiersResearching the Overlap: Hepatic Encephalopathy and Dementia in Focus
Charles Turck, PharmD, BCPS, BCCCP
Jasmohan Bajaj, MD
The Impact of a Cholesterol-Lowering Medication on Alzheimer's Disease
NeuroFrontiersThe Impact of a Cholesterol-Lowering Medication on Alzheimer's Disease
Charles Turck, PharmD, BCPS, BCCCP
Dr. Robert J. Shmookler Reis, PhD
Dr. Srinivas Ayyadevara, PhD
How DDL-920 Could Help Restore Cognitive Function in Alzheimer's Patients
NeuroFrontiersHow DDL-920 Could Help Restore Cognitive Function in Alzheimer's Patients
Ashley Baker, MSN, PMHNP
Istvan Mody, PhD
- advertisement
Public Health Disparities in Alzheimer's Disease and Brain Health
NeuroFrontiersPublic Health Disparities in Alzheimer's Disease and Brain Health
How Alzheimer's and Lewy Body Pathology Impact CAA Risk Factors
NeuroFrontiersHow Alzheimer's and Lewy Body Pathology Impact CAA Risk Factors
Charles Turck, PharmD, BCPS, BCCCP
Jagan Pillai, MD, PhD
Toxic Short RNAs May Cause Neuronal Cell Death in Alzheimer’s Disease
NeuroFrontiersToxic Short RNAs May Cause Neuronal Cell Death in Alzheimer’s Disease
Andrew Wilner, MD, FACP, FAAN
Marcus E. Peter, PhD